查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016498

前列腺癌治療市場報告：按藥物類型、分銷管道和地區分類（2026-2034 年）

Prostate Cancer Treatment Market Report by Drug Type (Chemotherapy, Biological Therapy, Hormone Therapy, and Others), Distribution Channel (Hospitals Pharmacies, Drug Stores and Retail Pharmacies, Online Pharmacies), and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球攝護腺癌治療市場規模達84億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到127億美元，2026年至2034年的複合年成長率為4.52%。推動市場成長的因素包括：前列腺癌盛行率的上升、個人化醫療的進步、新治療方法的出現、醫療保健支出的成長以及公眾對前列腺健康和可用治療方案的認知不斷提高。

前列腺癌治療市場趨勢：

個人化醫療和基因組學的進展：

前列腺癌治療市場概覽顯示，個人化醫療（根據患者的基因資訊為其量身定做醫療方案）正在推動市場擴張。在前列腺癌治療中，基因組分析有助於識別可能影響癌症行為的特定突變和基因表現。此外，全球已登記的前列腺癌病例超過375,304例，因此，對個人化醫療的需求日益成長，醫療專業人員可以根據患者的基因譜選擇最有效的治療方法。這種客製化治療方案能夠提高療效並最大限度地減少不良副作用，從而促進前列腺癌治療市場的成長。

先進治療方法的出現：

隨著新一代荷爾蒙療法、免疫療法和標靶治療等先進治療方法的引入，前列腺癌的治療模式正在不斷演變。荷爾蒙療法，包括新型雄性激素軸抑制劑，透過抑制利用雄性激素進行增殖和存活的癌細胞的生長，在治療前列腺癌方面展現出顯著療效。免疫療法能夠幫助免疫系統辨識並攻擊癌細胞，其價值日益凸顯。例如，研究表明，每20名晚期前列腺癌患者中就有1名對免疫療法帕博利珠單抗（Pembrolizumab）有反應。此外，標靶治療的出現也推動了前列腺癌治療需求的成長。標靶療法專注於癌症發展過程中涉及的特定路徑和機制，與傳統化療相比，它能夠提供更具針對性的治療方案，且副作用可能更少。

人們對聯合治療的興趣日益濃厚：

尤其是在晚期前列腺癌的治療中，聯合治療的使用日益增多，旨在提高治療效果。將不同類型的治療方法結合，例如放射線治療和荷爾蒙療法，或化療和新型生物製藥，可以對癌細胞進行多管齊下的攻擊，並已被證明能夠改善治療效果。當前列腺癌對傳統治療方法無反應時，這種方法尤其有效。臨床試驗正在持續探索各種聯合療法，以確定最有效的治療方案。在一項研究中，5% 的患者達到完全緩解，47% 的患者達到確認的部分緩解，28% 的患者病情穩定，21% 的患者病情進展。這凸顯了這些療法在前列腺癌治療中的潛力。因此，對聯合治療的投資正在增加，以提高患者的整體存活率和生活品質，這對前列腺癌治療市場的前景產生了積極影響。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球前列腺癌治療市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依藥物類型分類

  • 化療
  • 生物製藥
  • 荷爾蒙療法
  • 其他

第7章 市場區隔：依分銷通路分類

  • 醫院和藥房
  • 藥局和零售藥房
  • 網路藥房

第8章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第9章 SWOT 分析

第10章：價值鏈分析

第11章：波特五力分析

第12章：價格分析

第13章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • Astellas Pharma US, Inc.
    • AstraZeneca
    • Bayer Corporation
    • Dendreon Pharmaceuticals LLC
    • Ferring BV
    • Johnson & Johnson
    • Novartis AG
    • sanofi-aventis US LLC
    • Tolmar, Inc.
Product Code: SR112026A6185

The global prostate cancer treatment market size reached USD 8.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 12.7 Billion by 2034, exhibiting a growth rate (CAGR) of 4.52% during 2026-2034. The increasing prevalence of the disease, advancements in personalized medicine, the emergence of new therapies, higher healthcare spending, and growing public awareness about prostate health and available treatment options are strengthening the market growth.

PROSTATE CANCER TREATMENT MARKET ANALYSIS:

  • Major Market Drivers: The rising incidence of prostate cancer across the globe is significantly driving the market, as increasing numbers of cases necessitate more robust treatment solutions. In addition to this, ongoing advancements in personalized medicine and genomics are enabling more precise and effective treatments, thereby propelling the market growth.
  • Key Market Trends: The use of combination therapies in treating prostate cancer, which involves using multiple treatment modalities simultaneously to enhance efficacy and patient outcomes, is one of the major prostate cancer treatment market trends. In confluence with this, targeted and personalized therapies are becoming more valuable. These therapies utilize the patient's tumor's genetic profile to customize treatment, propelling the market growth.
  • Geographical Trends: The prostate cancer treatment market forecast indicates North America as the leading region due to its advanced healthcare infrastructure, high healthcare expenditure, and proactive cancer screening programs. Besides this, Asia-Pacific is experiencing rapid growth in the market, driven by increasing healthcare awareness, rising healthcare spending, and improvements in healthcare infrastructure.
  • Competitive Landscape: Some of the major market players in the prostate cancer treatment industry include Astellas Pharma US, Inc., AstraZeneca, Bayer Corporation, Dendreon Pharmaceuticals LLC, Ferring B.V., Johnson & Johnson, Novartis AG, sanofi-aventis U.S. LLC, and Tolmar, Inc, among many others.
  • Challenges and Opportunities: The high cost of advanced treatments is one of the primary obstacles, which can make them inaccessible to patients in less developed areas. However, the prostate cancer treatment market has recent opportunities for healthcare providers and insurers to innovate in cost management and patient financing models. Besides this, the market also faces regulatory challenges that can delay drug approvals and market entry. Nonetheless, ongoing research and collaboration among pharmaceutical companies and academic institutions present lucrative prospects for breakthroughs in treatment options and strategies.

PROSTATE CANCER TREATMENT MARKET TRENDS:

Advancements in Personalized Medicine and Genomics:

Prostate cancer treatment market overview shows that personalized medicine, which involves tailoring medical treatment to the individual characteristics of each patient, based on genetic information is aiding in market expansion. In prostate cancer treatment, genomic profiling helps in identifying specific mutations and gene expressions that may influence the behavior of cancer. Moreover, with more than 375,304 registered cases of prostate cancer across the globe, there is a growing demand for personalized medicines, which enables healthcare providers to choose therapies that are most likely to work based on the patient's genetic profile. Such tailored treatments increase efficacy and minimize unwanted side effects, thus supporting the prostate cancer treatment market growth.

Emergence of Advanced Therapeutic Options:

The treatment landscape for prostate cancer has evolved with the introduction of advanced therapeutic options such as new-generation hormone therapies, immunotherapies, and targeted therapies. Hormone therapies, such as new androgen axis drugs, have shown significant effectiveness in managing prostate cancer by inhibiting the growth of cancer cells that use androgens to grow and survive. Immunotherapies that help the immune system recognize and combat cancer cells are also gaining value. For instance, according to the research, one in twenty men with end-stage prostate cancer responded to the immunotherapy pembrolizumab. Furthermore, the emergence of targeted therapies, which concentrate on particular pathways or mechanisms involved in the development of cancer, thereby providing a more focused treatment approach with potentially fewer side effects compared to conventional chemotherapy is boosting the prostate cancer treatment demand.

Increasing Focus on Combination Therapies:

There is a growing trend towards the use of combination therapies to enhance treatment efficacy, particularly in advanced stages of prostate cancer. Combining different types of treatments, such as radiation therapy with hormone therapy or chemotherapy with new biologics, has been found to improve outcomes by attacking cancer cells in multiple ways. This method is especially helpful when prostate cancer refuses to respond to conventional therapies. Clinical trials are continuously exploring various combinations to determine the most effective protocols. In a study, 5% of patients achieved a complete response, 47% had a confirmed partial response, 28% maintained stable disease, and 21% experienced progressive disease, highlighting the potential of these therapies in prostate cancer treatment. Consequently, the increasing investments in combination therapies to increase the overall survival rate and quality of life for patients is positively impacting the prostate cancer treatment market outlook.

PROSTATE CANCER TREATMENT MARKET SEGMENTATION:

Breakup by Drug Type:

  • Chemotherapy
  • Biological Therapy
  • Hormone Therapy
  • Others

Hormone therapy accounts for the majority of the market share

Hormone therapy, also known as androgen deprivation therapy (ADT), holds a significant prostate cancer treatment market share due to its effectiveness in managing prostate cancer, particularly in its advanced stages. Prostate cancer growth is fueled by androgens, including testosterone. By limiting the synthesis of these androgens or inhibiting their impact on prostate cancer cells, hormone therapy slows or stops the disease's progression. This method is pivotal for patients whose cancer has metastasized beyond the prostate gland and for those who are not candidates for surgery or radiation. Additionally, hormone therapy is frequently used in combination with other treatments, such as radiation therapy, to improve outcomes, particularly in high-risk localized cancers, which is further bolstering the prostate cancer treatment industry.

Breakup by Distribution Channel:

  • Hospitals Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Pharmacies

Hospitals pharmacies hold the largest share of the industry

Hospital pharmacies are the leading segment propelling the prostate cancer treatment market revenue due to the complex nature of cancer treatment which often requires specialized medications that are administered under strict medical supervision. Hospital settings provide the integrated healthcare services necessary for the multifaceted approach needed in cancer treatment, including surgery, chemotherapy, radiation, and hormone therapy. These treatments, particularly chemotherapeutic agents and advanced immunotherapies, often require precise handling, storage conditions, and administration protocols that are best managed within hospital pharmacies. Additionally, the immediate availability of pharmaceuticals in hospital pharmacies ensures timely treatment, which is crucial for cancer care. Furthermore, the centralized care model of hospitals, coupled with the need for specialized care protocols for prostate cancer, reinforces the dominant role of hospital pharmacies in the industry, fostering market expansion.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest prostate cancer treatment market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for prostate cancer treatment.

Prostate cancer treatment market analysis revealed North America as the leading region due to its advanced healthcare infrastructure, high healthcare spending, and strong presence of leading pharmaceutical and biotechnology companies engaged in cancer research and drug development. The region benefits from a robust regulatory framework supportive of rapid advancements in medical technologies and therapeutic approaches, including new drug approvals and innovative treatment modalities. Additionally, there is a high awareness of prostate cancer risks and symptoms among the population, coupled with widespread screening practices that lead to early detection and treatment. This early detection significantly contributes to better treatment outcomes and sustained investments in prostate health. Moreover, the presence of some of the world's leading cancer research institutions in North America, such as the National Cancer Institute and top-tier universities, drives continuous innovation and improvement in prostate cancer therapies, further solidifying the region's leading position in the global market.

COMPETITIVE LANDSCAPE:

The market is highly competitive, featuring a mix of established pharmaceutical giants and specialized biotech firms. Astellas Pharma Inc. and AstraZeneca plc are prominent prostate cancer treatment companies known for their innovative therapies and significant R&D investments in oncology. They have expanded their portfolio with targeted treatments and are focusing on immunotherapies for advanced prostate cancer. These companies are also offering effective chemotherapeutic and hormonal treatments. They are also focusing on the development of therapies with improved efficacy and reduced side effects. The key players leverage their vast global networks to distribute and develop next-generation treatments.

The report provides a comprehensive analysis of the competitive landscape in the global prostate cancer treatment market with detailed profiles of all major companies, including:

  • Astellas Pharma US, Inc.
  • AstraZeneca
  • Bayer Corporation
  • Dendreon Pharmaceuticals LLC
  • Ferring B.V.
  • Johnson & Johnson
  • Novartis AG
  • sanofi-aventis U.S. LLC
  • Tolmar, Inc.

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global prostate cancer treatment market in 2025?

2. What is the expected growth rate of the global prostate cancer treatment market during 2026-2034?

3. What are the key factors driving the global prostate cancer treatment market?

4. What has been the impact of COVID-19 on the global prostate cancer treatment market?

5. What is the breakup of the global prostate cancer treatment market based on drug type?

6. What is the breakup of the global prostate cancer treatment market based on the distribution channel?

7. What are the key regions in the global prostate cancer treatment market?

8. Who are the key players/companies in the global prostate cancer treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Prostate Cancer Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Chemotherapy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Biological Therapy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Hormone Therapy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospitals Pharmacies
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Drug Stores and Retail Pharmacies
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Pharmacies
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Astellas Pharma US, Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 AstraZeneca
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Bayer Corporation
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Dendreon Pharmaceuticals LLC
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
    • 13.3.5 Ferring B.V.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
    • 13.3.6 Johnson & Johnson
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Novartis AG
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 sanofi-aventis U.S. LLC
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Tolmar, Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio

List of Figures

  • Figure 1: Global: Prostate Cancer Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Prostate Cancer Treatment Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Prostate Cancer Treatment Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Prostate Cancer Treatment Market: Breakup by Drug Type (in %), 2025
  • Figure 5: Global: Prostate Cancer Treatment Market: Breakup by Distribution Channel (in %), 2025
  • Figure 6: Global: Prostate Cancer Treatment Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Prostate Cancer Treatment (Chemotherapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 8: Global: Prostate Cancer Treatment (Chemotherapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 9: Global: Prostate Cancer Treatment (Biological Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Prostate Cancer Treatment (Biological Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Prostate Cancer Treatment (Hormone Therapy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Prostate Cancer Treatment (Hormone Therapy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Prostate Cancer Treatment (Other Drug Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Prostate Cancer Treatment (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Prostate Cancer Treatment (Hospitals Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Prostate Cancer Treatment (Hospitals Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Prostate Cancer Treatment (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Prostate Cancer Treatment (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Prostate Cancer Treatment (Online Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Prostate Cancer Treatment (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: North America: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: North America: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: United States: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: United States: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Canada: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Canada: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Asia-Pacific: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Asia-Pacific: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: China: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: China: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Japan: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Japan: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: India: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: India: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: South Korea: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: South Korea: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: Australia: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: Australia: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Indonesia: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Indonesia: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Others: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Others: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Europe: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Europe: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Germany: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Germany: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: France: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: France: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: United Kingdom: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: United Kingdom: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Italy: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Italy: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Spain: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Spain: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Russia: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Russia: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Others: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Others: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Latin America: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Latin America: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Brazil: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Brazil: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Mexico: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Mexico: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Others: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Others: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Middle East and Africa: Prostate Cancer Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Middle East and Africa: Prostate Cancer Treatment Market: Breakup by Country (in %), 2025
  • Figure 69: Middle East and Africa: Prostate Cancer Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Global: Prostate Cancer Treatment Industry: SWOT Analysis
  • Figure 71: Global: Prostate Cancer Treatment Industry: Value Chain Analysis
  • Figure 72: Global: Prostate Cancer Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Prostate Cancer Treatment Market: Key Industry Highlights, 2025 & 2034
  • Table 2: Global: Prostate Cancer Treatment Market Forecast: Breakup by Drug Type (in Million USD), 2026-2034
  • Table 3: Global: Prostate Cancer Treatment Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 4: Global: Prostate Cancer Treatment Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 5: Global: Prostate Cancer Treatment Market: Competitive Structure
  • Table 6: Global: Prostate Cancer Treatment Market: Key Players